Addendum to Evidence for the Detection of Non-Endotoxin Pyrogens by the Whole Blood Monocyte Activation Test

Nina Hasiwa1,2, Mardas Daneshian1, Peter Bruegger4, Stefan Fennrich5, Astrid Hochadel2, Sebastian Hoffmann6, Felix E. Rivera-Mariani3, Christoph Rockel7, Stefanie Schindler8, Ingo Spreitzer9, Sandra Stoppelkamp5, Kranthi Vysyaraju3, and Thomas Hartung1,3

1CAAT-europe, University of Konstanz, Konstanz, Germany; 2Atax-Advice, Konstanz, Germany; 3Johns Hopkins University, Bloomberg School of Public Health, CAAT, Baltimore, USA; 4Novartis, Basel, Switzerland; 5Department of Thoracic, Cardiac and Vascular Surgery, Tübingen University Hospital, Tübingen, Germany; 6seh consulting + services, Paderborn, Germany; 7Enzler Hygiene AG, Center for Hygiene, Pratteln, Switzerland; 8Animalfree Research, Zürich, Switzerland; 9Paul-Ehrlich Institut (PEI), Langen, Germany

Regarding this t4 report, which appeared in ALTEX (2013), 30(2), as co-author Thomas Hartung would like to acknowledge that the respective patents referred to, which he holds as the co-inventor of the whole blood pyrogen test, were at the time of the article licensed to Biotest Pharmaceuticals, Germany, and he received royalties from sales of this test. The license and associated royalty payment obligations were in the meantime transferred to Merck-Millipore, France.

http://dx.doi.org/10.14573/altex.1410081